Dr. Reddy’s Laboratories saw the highest growth of 1.99% in patent filings and 0.99% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.29% and grants by 0.32%. GlobalData’s DataBook provides a comprehensive analysis of Dr. Reddy’s Laboratories’s patent filings and grants. Buy the databook here.
Dr. Reddy's Laboratories has been focused on protecting inventions in United States(US) with six publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 31% filings and 67% grants. The United States(US), European Patent Office(EPO), China(CN), and Colombia(CO) patent Office are among the top ten patent offices where Dr. Reddy's Laboratories is filings its patents. Among the top granted patent authorities, Dr. Reddy's Laboratories has 67% of its grants in United States(US).
Roche and Johnson & Johnson could be the strongest competitors for Dr. Reddy's Laboratories
Patents related to rare diseases and climate change lead Dr. Reddy's Laboratories's portfolio
Dr. Reddy's Laboratories has the highest number of patents in rare diseases followed by, climate change and genomics. For rare diseases, nearly 50% of patents were filed and 50% of patents were granted in Q2 2024.
Melanoma related patents lead Dr. Reddy's Laboratories portfolio followed by prostate cancer, and sarcomas
Dr. Reddy's Laboratories has highest number of patents in melanoma followed by prostate cancer, sarcomas, multiple myeloma (kahler disease), and colon cancer. For melanoma, nearly 2% of patents were filed and 1% of patents were granted in Q2 2024.
For comprehensive analysis of Dr. Reddy's Laboratories's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.